Physician profile
Om Sam
NPI 1457845588
$3,071.11
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,155 · 2023: $1,366 · 2024: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $314.01 | 2022-2024 | Shingrix, Bexsero, Arexvy |
| Novo Nordisk INC | $300.62 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.44 | 2022-2024 | Xifaxan, Plenvu |
| Novartis Pharmaceuticals Corporation | $230.75 | 2022-2024 | |
| Lilly USA, LLC | $208.17 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $207.60 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $162.80 | 2022-2024 | Prolia, Evenity, Krystexxa |
| Biohaven Pharmaceutical Holding Company Ltd. | $156.62 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $140.60 | 2023 | Farxiga, Breztri |
| Dexcom, INC. | $111.09 | 2022-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $110.08 | 2022-2024 | Xarelto |
| Abbvie INC. | $103.89 | 2022-2024 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $102.15 | 2022-2023 | |
| Exact Sciences Corporation | $90.95 | 2023-2024 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $82.12 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $80.99 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.54 | 2022-2023 | |
| Sobi, INC | $42.08 | 2022-2023 | |
| Pfizer INC. | $41.99 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $40.18 | 2023 | Seglentis, Livalo |
| Phathom Pharmaceuticals, INC. | $33.43 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $31.98 | 2022 | |
| Valinor Pharma, LLC | $30.39 | 2023 | Movantik |
| Ultragenyx Pharmaceutical INC. | $22.38 | 2023 | |
| Ironwood Pharmaceuticals, INC | $20.38 | 2023 | Linzess |
| Abiomed | $20.18 | 2024 | Impella |
| Celgene Corporation | $19.73 | 2024 | Zeposia |
| Shield Therapeutics INC | $17.67 | 2023 | Accrufer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.52 | 2023 | |
| Convatec INC. | $11.95 | 2022 | |
| Sumitomo Pharma America, INC. | $9.83 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Om Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.